A protein tyrosine phosphatase 4A (PTP4A or PRL) targeting amino acid molecule is provided. The PRL targeting amino acid molecule includes an amino acid sequence according to one or more of NB91 (SEQ ID NO: 1), NB 13 (SEQ ID NO: 2), NB90 (SEQ ID NO: 3), NB4 (SEQ ID NO: 4), NB7 (SEQ ID NO: 5), NB10 (SEQ ID NO: 6), NB16 (SEQ ID NO: 7), NB18 (SEQ ID NO: 8), NB29 (SEQ ID NO: 9), NB19 (SEQ ID NO: 10), NB84 (SEQ ID NO: 11), NB92 (SEQ ID NO: 12), NB23 (SEQ ID NO: 13), NB26 (SEQ ID NO: 14), NB28 (SEQ ID NO: 15), NB68 (SEQ ID NO: 16), or a variant thereof. Also provided herein are methods of making and using the PRL targeting amino acid molecule.

Provided herein are methods for identifying pairs of protein binding partners, mutations of which may inform the discovery of pharmaceutically useful small molecules. The methods disclosed herein may allow for the adaptation of the native protein degradation system to modulate specific disease targets at the protein level, in particular, for targets that have long been considered undruggable.

The present disclosure provides methods to identify peptides and small molecule moieties that are able to functionally bridge an interaction between a target protein and an E3 ubiquitin ligase to mediate the degradation of the target protein. Some moieties can degrade specific target variants, but not others. The moieties create a neosubstrate for an E3 ligase of interest. The methods described enable generation of compounds able to selectively degrade specific targets within cells with implications for drug development for pathological conditions. The disclosure also describes the generation of modified peptides using post-translational modification enzymes, such as N-methyltransferases, prolyloligopeptidases, lactamases, hydroxylases, and dehydratases, along with methods of using the same.

Bacterial systems for analyzing ubiquitination of proteins is disclosed herein. Kits for analyzing the ubiquitination and methods for carrying out the analysis are also disclosed.

The present invention relates to new BARD1 isoforms specific to lung cancer and colorectal cancer, a method for detecting thereof and a method for treating and/or preventing lung cancer and colorectal cancer.

Bacterial systems for analyzing ubiquitination of proteins is disclosed herein. Kits for analyzing the ubiquitination and methods for carrying out the analysis are also disclosed.

Biomarkers are provided that are predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing Graft-Versus-Host Disease.

The present invention relates to a composition for regulating the differentiation of osteoclasts, and is very effective in preventing or treating bone-related diseases by effectively maintaining bone homeostasis by regulating bone metabolism, particularly the differentiation of bone marrow cells into osteoclasts.

Described are methods for the treatment of individuals having or as risk for having Macrophage Activation Syndrome (MAS). The disclosed methods may include the steps of detecting a tripartite motif 8 (TRIM8) protein level or a tripartite motif 8 (TRIM8) mRNA level in abiological sample obtained from an individual, and providing a treatment to said individual based on the level of TRIM8 protein and/or mRNA detected. Individuals identified as being high risk for MAS may be treated with an immunosuppressive therapy as disclosed herein.

Identifying and classifying a liver condition in a human subject based on a blood sample obtained from the human subject in a system being functionally associated with at least one analyzer for analyzing the blood sample is disclosed. The system includes at least one of an input interface or a transceiver, one or more processors, and a computer readable storage medium for instructions execution by the processor(s). The storage medium has stored instructions to receive biographical information relating to the human subject, and instructions to receive, from the analyzer(s), measurements of a plurality of serum biomarkers. The storage medium further has stored instructions to apply a neural network algorithm to the received measurements and biographical information, and instructions to identify, based on an output of the neural network algorithm, the presence of a liver condition, and to classify a severity of the liver condition.